Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Equillium, Inc.

NASDAQ: EQ · Life Sciences · 4 alerts · CIK 1746466

Share price
$1.15Close, Nov 16
Market cap
$94.7M
Shares outstanding
82.32MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Equillium, Inc. filings on SEC EDGAR ↗

4:16 PM ET 10-Q
Financial Results

Equillium Q3 2026 Results: Net Loss of $4.58M, Loss Widens

Equillium, Inc. reported a net loss of $4.6 million for the third quarter of 2026, with cash and cash equivalents increasing to $53.3 million as of September 30, 2026, following a private placement. Subsequent to the quarter-end, the company raised an additional $20.0 million in gross proceeds, which management believes will fund operations for at least the next 12 months.

Key figure
Net loss $4.58M
4:11 PM ET 8-K
Financial Results

Equillium Financial Results

Equillium reported third quarter 2026 financial results, highlighting the initiation of a Phase 1 clinical trial for EQ504 with proof-of-mechanism data expected in Q2 2027. The company strengthened its balance sheet with a $20 million financing tranche closed in October 2026, extending its cash runway into 2029.

“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program. We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease.”

Bruce Steel, Chief Executive Officer of Equillium

“We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027. Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”

Bruce Steel, Chief Executive Officer of Equillium
5:09 PM ET 8-K
Capital Raise

Equillium Capital Raise of $20M

Equillium triggered a $20 million milestone closing of a previously announced private placement following the dosing of the first patient in its Phase 1 clinical trial of EQ504. The company is issuing approximately 14.9 million shares and 20.1 million pre-funded warrants to institutional and accredited investors. The proceeds are expected to extend the company's cash runway into 2029.

Value
$20M
5:07 PM ET 8-K
Regulatory Approval

Equillium Regulatory Approval

Equillium received clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification scheme to initiate a Phase 1 clinical trial of EQ504. The study will evaluate the safety and pharmacokinetics of the oral drug in healthy participants, with dosing expected to begin in early November 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.